Investigational Drug Information for Afuresertib
✉ Email this page to a colleague
What is the development status for investigational drug Afuresertib?
Afuresertib is an investigational drug.
There have been 13 clinical trials for Afuresertib.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 8th 2012.
The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Ovarian Neoplasms. The leading clinical trial sponsors are Laekna Limited, Novartis Pharmaceuticals, and GlaxoSmithKline.
Summary for Afuresertib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 252 |
| WIPO Patent Applications | 185 |
| Japanese Patent Applications | 29 |
| Clinical Trial Progress | Phase 2 (2012-02-08) |
| Vendors | 39 |
Recent Clinical Trials for Afuresertib
| Title | Sponsor | Phase |
|---|---|---|
| Human Mass Balance and Biotransformation Study of [14C]Afuresertib | Laekna Limited | Phase 1 |
| Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | Laekna Limited | Phase 1/Phase 2 |
| Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer | Laekna LLC | Phase 1 |
Clinical Trial Summary for Afuresertib
Top disease conditions for Afuresertib
Top clinical trial sponsors for Afuresertib
US Patents for Afuresertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
